National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Childhood Visual Pathway and Hypothalamic Glioma Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 04/07/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Treatment Option Overview






Untreated Childhood Visual Pathway and Hypothalamic Glioma






Recurrent Childhood Visual Pathway and Hypothalamic Glioma






Get More Information From NCI






Changes to This Summary (04/07/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Cellular Classification

Childhood visual pathway and hypothalamic gliomas are usually low-grade (grades 1 and 2) astrocytomas. Both pilocytic astrocytomas and fibrillary astrocytomas may occur. The pilomyxoid variant of pilocytic astrocytoma occurs in the visual pathway and may be a more aggressive variant and more likely to disseminate.[1] Visual pathway gliomas include astrocytic tumors of the optic nerve, optic chiasm, and optic tract. Because of the infiltrative nature of such lesions, separation of visual pathway and hypothalamic gliomas from thalamic tumors is often difficult and arbitrary. Malignant gliomas of the visual pathway are rare. Visual pathway gliomas occur at an increased incidence in patients with neurofibromatosis type 1 (NF-1); approximately 20% of all patients with NF-1 will develop a visual pathway glioma. In these patients, the tumor may be found on screening evaluations when the child is asymptomatic or has apparent static neurologic and/or visual deficits. Pathologic confirmation is frequently not obtained in asymptomatic patients, and when biopsies have been performed, these tumors have been found to be predominantly pilocytic (grade 1) rather than fibrillary (grade 2) astrocytomas.[2-5]

References

  1. Komotar RJ, Burger PC, Carson BS, et al.: Pilocytic and pilomyxoid hypothalamic/chiasmatic astrocytomas. Neurosurgery 54 (1): 72-9; discussion 79-80, 2004.  [PUBMED Abstract]

  2. Kleihues P, Cavenee WK, eds.: Pathology and Genetics of Tumours of the Nervous System. Lyon, France: International Agency for Research on Cancer, 2000. 

  3. Listernick R, Darling C, Greenwald M, et al.: Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 127 (5): 718-22, 1995.  [PUBMED Abstract]

  4. Burger PC, Scheithauer BW: Tumors of the Central Nervous System. Washington, DC: Armed Forces Institute of Pathology,1994. 

  5. Allen JC: Initial management of children with hypothalamic and thalamic tumors and the modifying role of neurofibromatosis-1. Pediatr Neurosurg 32 (3): 154-62, 2000.  [PUBMED Abstract]

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov